We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 26, 2018

Eribulin Mesylate as Third- or Subsequent-Line Chemotherapy in Elderly Patients With Locally Recurrent or Metastatic Breast Cancer

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Eribulin Mesylate as Third or Subsequent Line Chemotherapy in Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
Oncologist 2018 Nov 09;[EPub Ahead of Print], S Leo, E Arnoldi, L Repetto, Z Coccorullo, S Cinieri, M Fedele, M Cazzaniga, V Lorusso, A Latorre, G Campanella, M Ciccarese, C Accettura, S Pisconti, A Rinaldi, C Brunetti, M Raffaele, L Coltelli, S Spazzapan, L Fratino, L Petrucelli, L Biganzoli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading